Your shopping cart is currently empty

Bimatoprost (AGN 192024) is a cloprostenol-derived amide that is used as an antihypertensive agent in the treatment of open-angle glaucoma and ocular hypertension.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $30 | In Stock | In Stock | |
| 5 mg | $43 | In Stock | In Stock | |
| 10 mg | $73 | In Stock | In Stock | |
| 25 mg | $136 | In Stock | In Stock | |
| 50 mg | $243 | In Stock | In Stock | |
| 100 mg | $413 | In Stock | In Stock | |
| 200 mg | $607 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $48 | In Stock | In Stock |
| Description | Bimatoprost (AGN 192024) is a cloprostenol-derived amide that is used as an antihypertensive agent in the treatment of open-angle glaucoma and ocular hypertension. |
| In vitro | Bimatoprost is an effective prostaglandin FP receptor agonist, capable of directly inducing a robust and rapid return of calcium ions to baseline levels. It directly activates FP prostaglandin receptors in rats, mice, and humans. |
| In vivo | Bimatoprost displaces [3H] prostaglandin F (2alpha) binding to FP receptors with a Ki of 6.31 μM. It rapidly mobilizes intracellular calcium in 3T3 mouse fibroblasts expressing FP receptors (EC50: 2.2 μM) and human embryonic kidney cells with human FP receptors (EC50: 2.94 μM). Bimatoprost upregulates Cyr61 expression in feline irises and mildly stimulates aqueous humor outflow rate, increasing it by 13% during the day and 14% at night, while reducing tonographic outflow by 26%, thereby lowering intraocular pressure. |
| Synonyms | AGN 192024 |
| Molecular Weight | 415.57 |
| Formula | C25H37NO4 |
| Cas No. | 155206-00-1 |
| Smiles | CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCc1ccccc1 |
| Relative Density. | 1.145 g/cm3 |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (601.58 mM), Sonication is recommended. Ethanol: 77 mg/mL (185.29 mM), Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.81 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.